Evidence map›Paper›PMID 42069591›Full record

ArticleHarm reduction journal2026

Transitions from first drug use to illicit opioid and injection drug use in a multisite rural U.S. cohort of people who use drugs.

Rob J Fredericksen, Adams Sibley, Kathryn E Lancaster, Wiley Jenkins, L Sarah Mixson, Bridget M Whitney, Lawrence Ouellet, Peter D Friedmann, Todd Korthuis, Joseph A C Delaney and 6 more

Abstract readMulticenter Study
In one paragraph

Article in Harm reduction journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Rob J FredericksenUniversity of Washington, 325 9th Avenue Seattle, Box 359931, Seattle, WA, 98104, USA. rfrederi@uw.edu.
Adams SibleyUniversity of North Carolina-Chapel Hill, 216 Lenoir Dr, Chapel Hill, NC, 27599, USA.
Kathryn E LancasterWake Forest University, 475 Vine St, Winston-Salem, NC, 27701, USA.
Wiley JenkinsClemson University, 535-A Edwards Hall, 201 Epsilon Zeta Drive, Clemson, 29634, USA.
L Sarah MixsonUniversity of Washington, 325 9th Avenue Seattle, Box 359931, Seattle, WA, 98104, USA.
Bridget M WhitneyUniversity of Washington, 325 9th Avenue Seattle, Box 359931, Seattle, WA, 98104, USA.
Lawrence OuelletSchool of Public Health, University of Illinois-Chicago, 1603 W. Taylor St, Chicago, IL, 60612, USA.
Peter D FriedmannUniversity of Massachusetts, 55 Lake Ave North, Worcester, MA, 01655, USA.
Todd KorthuisOregon Health & Science University, 3181 SW Sam Jackson Park Rd, Portland, OR, 97239, USA.
Joseph A C DelaneyUniversity of Washington, 325 9th Avenue Seattle, Box 359931, Seattle, WA, 98104, USA.
Judith I TsuiUniversity of Washington, 325 9th Avenue Seattle, Box 359931, Seattle, WA, 98104, USA.
Heidi M CraneUniversity of Washington, 325 9th Avenue Seattle, Box 359931, Seattle, WA, 98104, USA.
William ZuleRTI International, 3040 East Cornwallis Rd, Durham, NC, 27713, USA.
April M YoungUniversity of Kentucky College of Public Health, 111 Washington Ave, Lexington, KY, 40536, USA.
David W SealTulane University, 6823 St Charles Ave, New Orleans, LA, 70118, USA.
Thomas J StopkaTufts University School of Medicine, 136 Harrison Ave, Boston, MA, 02111, USA.

Funding

Ending transmission of HIV, HCV, and STDs and overdose in rural communities of people who inject drugs (ETHIC)UH3DA044829 · NIDA · UNIVERSITY OF CHICAGO · PI JENKINS, WILEY, PHO, MAI TUYET · 2019 to 2022
$5.2M
Kentucky Communities and Researchers Engaging to Halt the Opioid Epidemic (CARE2HOPE)UH3DA044798 · NIDA · UNIVERSITY OF KENTUCKY · PI COOPER, HANNAH LF, YOUNG, APRIL MARIE · 2019 to 2022
$4.4M
Oregon HIV/Hepatitis and Opioid Prevention and Engagement (OR-HOPE) Study Cost ExtensionUH3DA044831 · NIDA · OREGON HEALTH & SCIENCE UNIVERSITY · PI KORTHUIS, PHILIP TODD · 2019 to 2022
$4.0M
Drug Injection Surveillance and Care Enhancement for Rural Northern New England (DISCERNNE)UH3DA044830 · NIDA · BAYSTATE MEDICAL CENTER, INC. · PI FRIEDMANN, PETER D, STOPKA, THOMAS J · 2019 to 2022
$3.9M
Rural Comorbidity and HIV consequences of Opioid use Research and Treatment Initiative (Rural cohort)U24DA048538 · NIDA · UNIVERSITY OF WASHINGTON · PI CRANE, HEIDI M., TSUI, JUDITH · 2019 to 2023
$3.7M
Next-Generation Sequencing Center for GHOSTing Hepatitis C Virus: Transforming Community Based Molecular Surveillance and Outbreak InvestigationU24DA044801 · NIDA · MASSACHUSETTS GENERAL HOSPITAL · PI ALLEN, TODD M · 2017 to 2022
$3.3M
Understanding Health Inequities at the Intersection of the HIV and substance use epidemics across racial/ethnic and other underserved populationsR01DA058938 · NIDA · UNIVERSITY OF WASHINGTON · PI Heidi M. Crane, Rob Fredericksen · 2023 to 2026
$2.8M
Community-based, client-centered prevention homes to address the rural opioid epidemicUH3DA044826 · NIDA · UNIVERSITY OF WISCONSIN-MADISON · PI SEAL, DAVID W, WESTERGAARD, RYAN PATRICK · 2019 to 2022
$2.6M
Mitigating the Outcomes Associated with the Injection Drug Use Epidemic in Southern AppalachiaUH3DA044823 · NIDA · RESEARCH TRIANGLE INSTITUTE · PI ZULE, WILLIAM A · 2019 to 2021
$2.4M
Implementing a Community-Based Response to the Opioid Epidemic in Rural OhioUG3DA044822 · NIDA · OHIO STATE UNIVERSITY · PI GO, VIVIAN F., MILLER, WILLIAM C · 2017 to 2018
$1.1M
National Institute of Drug Abuse U24DA048538National Institute of Drug Abuse UG3DA044798National Institute of Drug Abuse UG3DA044823National Institute of Drug Abuse UG3DA044826National Institute of Drug Abuse UG3DA044829National Institute of Drug Abuse UG3DA044830National Institute of Drug Abuse UG3DA044831National Institute of Drug Abuse UH3DA044822NIDA NIH HHS R01 DA058938NIDA NIH HHS U24 DA044801NIDA NIH HHS U24 DA048538NIDA NIH HHS UG3 DA044822NIDA NIH HHS UH3 DA044798NIDA NIH HHS UH3 DA044823NIDA NIH HHS UH3 DA044826NIDA NIH HHS UH3 DA044829NIDA NIH HHS UH3 DA044830NIDA NIH HHS UH3 DA044831
6 · The paper itself

Abstract

aimTo understand circumstances surrounding transitions between initial drug use, non-prescribed opioid use, and injection drug use (IDU) among people who use non-prescribed opioids in the rural U.S.

methodsWe interviewed adults who use non-prescribed opioids in 10 states. We coded transcript data regarding age, drug, modality, circumstances for each "first use" event and transitions to illicit opioid use/IDU. Transition-related themes were categorized using the Social Ecological Model (SEM) through iterative qualitative memoing. We calculated frequencies and measures of central tendency.

resultsParticipants (n = 304, mean age [MA] = 36 years, 56% male) reported marijuana or opioid pills as first drug used (60%, reported MA = 13, and 16%, MA = 19, respectively). First opioid use (MA = 20) was typically pills (74%); 43% were initially prescribed opioids for pain. Of participants reporting IDU (92%, MA = 24), first drugs injected were methamphetamine (26%), opioid pills (22%), and heroin (22%). Reasons for first injection of these three substances were recreational (65%, 84%, 66%, respectively) followed by mental health coping (35%, 16%, 33%). Interviews revealed factors influencing transition to illicit opioid use/IDU at environmental, interpersonal, and intrapersonal levels of the SEM, including early household exposure to drugs, and family/peer encouragement to use opioids for coping. Participants described initial use of prescribed opioids following surgery or workplace injury, followed by illicit use of opioids and later IDU for recreational as well as practical goals. IDU was facilitated by intimate partners and friends in the context of diminished local access to illicit opioid pills.

conclusionAmong people who use opioids and inject drugs in the rural U.S., drug use typically started in pre-adolescence, first opioid use in early adulthood, and IDU a few years later, highlighting the need for early intervention. Methamphetamine comprised a substantial proportion of initial IDU raising concerns for polysubstance use. Drug use for coping highlights the need for increased mental health resources in rural areas.

Indexed as

Opioid-Related DisordersRural PopulationSubstance Abuse, IntravenousAdultAnalgesics, OpioidCohort StudiesFemaleHumansIllicit DrugsMaleMiddle AgedUnited StatesAnalgesics, OpioidIllicit DrugsDrug use initiationIllicit use of opioidsInjection drug useRural health

Identifiers

PMID42069591
PMCPMC13289511

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.